Table 1.
MIC (µg/mL) of aztreonam, alone and in association with BLIs, of tested strains.
| Strain | Metallo-β-Lactamase | Serine-β- Lactamase | MIC ATM | MIC ATM after Addition of | MIC ZID | MIC ATM/ZID 1:1 Ratio | REF | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLA a | TAZ b | SUL b | VAB c | AVI b | REL b | ZID d | |||||||
| E. coli CP-Ec3 | bla VIM-1 | bla KPC-2 | >32 | >32 | >32 | >32 | >32 | 8 | >32 | 32 | 1 | 1 | [16] |
| E. coli CP-Ec4 | bla VIM-1 |
bla
TEM-1 * bla CTX-M-15 * bla SHV-12 |
>32 | 16 | >32 | >32 | >32 | 32 | >32 | >32 | 1 | 1 | [16] |
| E. coli 482483 | bla NDM-5 |
bla
TEM-1 * bla CTX-M-15 |
>32 | 16 | >32 | >32 | >32 | 8 | >32 | 32 | 1 | 1 | [17] |
| C. amalonaticus N18 | bla VIM-1 | * bla SHV-12 | >32 | 8 | >32 | >32 | >32 | 0.25 | 4 | 0.5 | 4 | 0.5 | [18] |
|
K. pneumoniae
KL 12 SG |
bla NDM-1 |
bla
TEM-1 * bla CTX-M-15 |
>32 | >32 | >32 | >32 | 4 | 0.25 | 4 | 0.25 | 8 | 0.5 | This study |
| K. pneumoniae LC954/14 | bla NDM-1 |
* bla
CTX-M-15 * bla SHV-182 |
>32 | >32 | >32 | >32 | 8 | 0.25 | 4 | >32 | 1 | 1 | [19] |
| C. indologenes LC650/17 | bla IND-3 | * bla CIA | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | [20] |
| E. meningoseptica LC596/11 |
bla
B-9 bla GOB-13 |
* bla CME-1 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | [20] |
| S. maltophilia | bla L-1 | * bla L-2 | >32 | >32 | 4 | 8 | 2 | 1 | 0.5 | 0.5 | >32 | 0.5 | [20] |
MIC, minimum inhibitory concentration; BLIs, β-lactamase inhibitors; ATM, aztreonam; CLA, clavulanate; TAZ, tazobactam; SUL, sulbactam; VAB, vaborbactam; AVI, avibactam; REL, relebactam; ZID, zidebactam. a: 2 µg/mL; b: 4 µg/mL; c: 8 µg/mL; d: 0.5 µg/mL. * ESBL.